Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Taxotere

TAXOTERE 20 mg/0.5 mL concentrate and solvent for solution for infusion · Abschnitt 4.8 · PDF-Seite 12–13

HOS-084543 · Präparat HOS-083047

• 1 312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively. • 258 patients who received docetaxel in combination with doxorubicin. • 406 patients who received docetaxel in combination with cisplatin. • 92 patients treated with docetaxel in combination with trastuzumab. 12  • 255 patients who received docetaxel in combination with capecitabine. • 332 patients (TAX327) who received docetaxel in combination with prednisone or prednisolone (clinically important treatment related adverse events are presented). • 1276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented). • 300 gastric adenocarcinoma patients (221 patients in the phase III part of the study and 79 patients in the phase II part) who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented). • 174 and 251 head and neck cancer patients who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented). • 545 patients (STAMPEDE study) who received docetaxel in combination with prednisone or prednisolone and ADT.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.